Article

Carl Zeiss Meditec to initiate trial of ReLEx method

Carl Zeiss Meditec announced its intention to initiate a U.S. clinical trial of the ReLEx smile procedure for the correction of myopia, having received conditional approval for the trial from the FDA.

Chicago-Carl Zeiss Meditec announced its intention to initiate a U.S. clinical trial of the ReLEx smile procedure for the correction of myopia, having received conditional approval for the trial from the FDA.

Carl Zeiss Meditec developed the new ReLEx smile technique for refractive surgery, which combines femtosecond laser technology and precise lenticule extraction for minimally invasive laser vision correction-all in a single system (VisuMax Femtosecond Laser).

The ReLEx smile method generates a refractive lenticule in the intact cornea with the femtosecond laser. The surgeon then removes the lenticule through a less-than-4-mm incision without needing to move the patient to an excimer laser.

“We are pleased that we can now start this clinical trial as it represents the first milestone on our path to make this procedure available to surgeons in the United States,” said Ludwin Monz, PhD, president and chief executive officer of Carl Zeiss Meditec AG.

The VisuMax Laser Keratome is currently cleared in the United States for creating corneal flaps as well as for lamellar and penetrating keratoplasty for corneal transplantations. VisuMax ReLEx smile was launched internationally in September 2011.

Conditional approval to initiate the clinical trial was received April 20. Carl Zeiss Meditec is expecting to start enrolling patients in the U.S. clinical trial within the next few months.

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.